



MAIL STOP AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G.A. Demopoulos et al. Attorney Docket No.: OMER117356
Application No.: 09/839,633 Group Art Unit: 1646
Filed: April 20, 2001 Examiner: E.B. O'Hara
Title: METHOD OF INHIBITION OF PAIN AND INFLAMMATION DURING
SURGERY COMPRISING ADMINISTRATION OF SOLUBLE TNF
RECEPTORS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

January 13, 2005

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.


1. X Copies of the listed references are enclosed for the Examiner's use.
2. X Pursuant to 37 C.F.R. § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, and is accompanied by:
 - a. X a certification statement as specified in 37 C.F.R. § 1.97(e); or
 - b. the submission fee set forth in 37 C.F.R. § 1.17(p). Check No. in the amount of \$180.00 is enclosed.
3. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

appropriate length required upon the filing of any reply during the entire prosecution of this application.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}



Dennis K. Shelton

Registration No. 26,997

Direct Dial No. 206.695.1718

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:

1/13/05



DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G.A. Demopulos et al. Attorney Docket No.: OMER117356
Application No.: 09/839,633 Group Art Unit: 1646
Filed: April 20, 2001 Examiner: E.B. O'Hara
Title: METHOD OF INHIBITION OF PAIN AND INFLAMMATION DURING
SURGERY COMPRISING ADMINISTRATION OF SOLUBLE TNF
RECEPTORS

CERTIFICATION STATEMENT UNDER 37 C.F.R. § 1.97(e) AND/OR § 1.704(d)


TO THE COMMISSIONER FOR PATENTS:

1. I, the person signing below, state that no item of information contained in the accompanying Second Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge as the person signing this certification after making reasonable inquiry, no item of information contained in the accompanying information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

2. I, the person signing below, am the attorney or agent who prepared or prosecuted the application, signing on the basis of the information supplied by another individual designated in 37 C.F.R. § 1.56(c).

Respectfully submitted,


CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLLC}


Dennis K. Shelton
Registration No. 26,997
Direct Dial No. 206.695.1718

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:

1/13/05


Carole Gulyan

DKS:cj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



**INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL
TO THE PROSECUTION OF THE SUBJECT APPLICATION**

Applicants: Gregory A. Demopoulos et al. Attorney Docket No: PH.1.0017.US2
Serial No: 09/839,633 Group Art Unit: 1646 OMER117356
Filed: April 20, 2001 Examiner: Eileen B. O'Hara
Title: METHOD OF INHIBITION OF PAIN AND INFLAMMATION DURING
SURGERY COMPRISING ADMINISTRATION OF SOLUBLE TNF
RECEPTORS

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	ID	Document Information
_____	O01669	Sander, O., et al., "Therapy of refractory chronic polyarthritis with tumor necrosis factor alpha receptor fusion protein (TNFR55-IgG1)—long term follow-up of 80 personal cases," <i>Z. Rheumatol.</i> 57 :307 (1998) (Abstract only).
_____	O01670	Fenner, H., "Immunopharmacologic profile and therapeutic prospects of anti-TNF-alpha therapy," <i>Z. Rheumatol.</i> 57 :294 (1998) (Abstract only).
_____	O01671	Breedveld, F., "New tumor necrosis factor-alpha biologic therapies for rheumatoid arthritis," <i>Eur. Cytokine Netw.</i> 9 :233 (1998) (Abstract only).
_____	O01672	Qiang, X., et al., "Gliclazide inhibits diabetic neuropathy irrespective of blood glucose levels in streptozotocin-induced diabetic rats," <i>Metabolism</i> 47 :977 (1998) (Abstract only).
_____	O01673	Hori, T., et al., "Pain modulatory actions of cytokines and prostaglandin E2 in the brain," <i>Ann. N.Y. Acad. Sci.</i> 840 :269 (1998) (Abstract only).
_____	O01674	Sommer, C., et al., "Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1," <i>Exp. Neurol.</i> 151 :138 (1998) (Abstract only).

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688

- _____ O01675 Chou, R.C., et al., "Adrenergic regulation of macrophage-derived tumor necrosis factor-alpha generation during a chronic polyarthritis pain model," *J. Neuroimmunol.* **82**:140 (1998) (Abstract only).
- _____ O01676 Camussi, G., et. al., "The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis," *Drugs* **55**:613 (1998) (Abstract only).
- _____ O01677 Sommer, C. et al., "The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve," *Pain* **74**:83 (1998) (Abstract only).

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MSK:sj

OMEROS CORPORATION
1420 Fifth Avenue
Suite 2600
Seattle, Washington 98101
206.623.4688